Ziritaxestat

N/A

Report date: 2025/06/22 20:00:04
NME

Base Information

Drug NameZiritaxestat
Drug Alias NameZiritaxestat - Galapagos/Gilead-SciencesGLPG-1690
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[28
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGalapagos Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A